跳至主要内容
临床试验/ISRCTN68997518
ISRCTN68997518已完成未知

Dietary omega-3 and omega-6 fatty acids supplementation in pregnant women with diabetes: a randomised, double-blind, placebo-controlled trial

ewham University Hospital NHS Trust (UK)0 个研究点目标入组 320 人开始时间: 2010年7月30日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
320

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • Current inclusion criteria as of 14/02/2012:
  • 1. Pregnant women aged 17-45 years old without any medical condition
  • 2. Pregnant women aged 17-45 years old with diabetes (type 2 diabetes or gestational diabetes)
  • Previous inclusion criteria:
  • 1. Pregnant women with or without diabetes (type 1, type 2, gestational diabetes)
  • 2. Eligible age: 17 - 40 years
  • 3. Control subjects without diabetes

排除标准

  • Current exclusion criteria as of 21/06/2013:
  • 1. Pregnancy with more than one foetus
  • 2. Known major foetal anomaly
  • 3. Current or planned corticosteroid therapy
  • 4. Asthma requiring medication
  • 5. Current or planned beta-adrenergic therapy
  • 6. Chronic medical conditions such as HIV/AIDS, kidney disease, or congenital heart disease
  • 7. Hematologic or autoimmune disease such as sickle cell disease, other hemoglobinopathies, lupus, or antiphospholipid syndrome
  • 8. Previous or planned tocolytic therapy to induce labour or increase contraction strength
  • Previous exclusion criteria until 21/06/2013:
  • 1. Smokers
  • 2. History of stillbirth or foetal death
  • 3. Pregnancy with more than one foetus
  • 4. Known major foetal anomaly
  • 5. Current or planned corticosteroid therapy
  • 6. Asthma requiring medication
  • 7. Current or planned beta-adrenergic therapy
  • 8. Chronic hypertension requiring medication within 6 months of or during pregnancy
  • 9. Chronic medical conditions such as HIV/AIDS, kidney disease, or congenital heart disease
  • 10. Hematologic or autoimmune disease such as sickle cell disease, other hemoglobinopathies, lupus, or antiphospholipid syndrome
  • 11.Maternal or foetal conditions likely to require preterm delivery, such as pre-eclampsia, preterm labour, or intrauterine growth retardation
  • 12. Previous or planned tocolytic therapy to induce labour or increase contraction strength
  • Previous exclusion criteria until 14/02/2012:
  • 1. Smokers
  • 2. History of stillbirth or foetal death
  • 3. Pregnancy with more than one foetus
  • 4. Known major foetal anomaly
  • 5. Asthma requiring medication
  • 6. Current or planned beta-adrenergic therapy
  • 7. Chronic hypertension requiring medication within 6 months of, or during, pregnancy
  • 8. Chronic medical conditions such as HIV/AIDS, kidney disease or congenital heart disease
  • 9. Haematologic or autoimmune disease such as sickle cell disease
  • 10. Other haemoglobinopathies
  • 11. Lupus or antiphospholipid syndrome
  • 12. Maternal or foetal conditions likely to require preterm delivery, such as pre-eclampsia, or intrauterine growth retardation

研究者

发起方
ewham University Hospital NHS Trust (UK)

相似试验